Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Share-based Compensation (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Share-based Compensation for 2 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 51.14% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.9 million through Dec 2025, down 44.19% year-over-year, with the annual reading at $11.9 million for FY2025, 44.19% down from the prior year.
  • Share-based Compensation hit $1.8 million in Q4 2025 for Prelude Therapeutics, down from $2.4 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.1 million in Q2 2024 to a low of $1.8 million in Q4 2025.